Search Results - "Awad, Mark M"

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study by Rudin, Charles M, Awad, Mark M, Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csőszi, Tibor, Cheema, Parneet K, Rodriguez-Abreu, Delvys, Wollner, Mirjana, Yang, James Chih-Hsin, Mazieres, Julien, Orlandi, Francisco J, Luft, Alexander, Gümüş, Mahmut, Kato, Terufumi, Kalemkerian, Gregory P, Luo, Yiwen, Ebiana, Victoria, Pietanza, M Catherine, Kim, Hye Ryun

“…Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604…”
Get full text

PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course by Nishino, Mizuki, Ramaiya, Nikhil H, Awad, Mark M, Sholl, Lynette M, Maattala, Jennifer A, Taibi, Myriam, Hatabu, Hiroto, Ott, Patrick A, Armand, Philippe F, Hodi, F Stephen

“…Investigate the clinical characteristics, radiographic patterns, and treatment course of PD-1 inhibitor-related pneumonitis in advanced cancer patients. Among…”
Get full text

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers by Ready, Neal, Hellmann, Matthew D, Awad, Mark M, Otterson, Gregory A, Gutierrez, Martin, Gainor, Justin F, Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S, Chesney, Jason, Orcutt, James, Spigel, David R, Reck, Martin, O'Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J, Szustakowski, Joseph D, Green, George, Chang, Han, Ramalingam, Suresh S

“…CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of…”
Get full text

False positive plasma genotyping due to clonal hematopoiesis by Hu, Yuebi, Ulrich, Bryan, Supplee, Julianna, Kuang, Yanan, Lizotte, Patrick H, Feeney, Nora, Guibert, Nicolas, Awad, Mark M, Wong, Kwok-Kin, Janne, Pasi A, Paweletz, Cloud Peter, Oxnard, Geoffrey R

“…Plasma cell-free DNA (cfDNA) genotyping is increasingly used in cancer care, but assay accuracy is debated. Because most cfDNA is derived from peripheral blood…”
Get full text

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer by Wang, Xinan, Ricciuti, Biagio, Nguyen, Tom, Li, Xihao, Rabin, Michael S, Awad, Mark M, Lin, Xihong, Johnson, Bruce E, Christiani, David C

“…Lung carcinogenesis is a complex and stepwise process involving accumulation of genetic mutations in signaling and oncogenic pathways via interactions with…”
Get full text

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status by Ricciuti, Biagio, Arbour, Kathryn C, Lin, Jessica J, Vajdi, Amir, Vokes, Natalie, Hong, Lingzhi, Zhang, Jianjun, Tolstorukov, Michael Y, Li, Yvonne Y, Spurr, Liam F, Cherniack, Andrew D, Recondo, Gonzalo, Lamberti, Giuseppe, Wang, Xinan, Venkatraman, Deepti, Alessi, Joao V, Vaz, Victor R, Rizvi, Hira, Egger, Jacklynn, Plodkowski, Andrew J, Khosrowjerdi, Sara, Digumarthy, Subba, Park, Hyesun, Vaz, Nuno, Nishino, Mizuki, Sholl, Lynette M, Barbie, David, Altan, Mehmet, Heymach, John V, Skoulidis, Ferdinandos, Gainor, Justin F, Hellmann, Matthew D, Awad, Mark M

“…STK11 and KEAP1 mutations (STK11 mutant [STK11 ] and KEAP1 ) are among the most often mutated genes in lung adenocarcinoma (LUAD). Although STK11 has been…”
Get more information

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study by Langer, Corey J, Dr Prof, Gadgeel, Shirish M, Prof, Borghaei, Hossein, DO, Papadimitrakopoulou, Vassiliki A, Prof, Patnaik, Amita, MD, Powell, Steven F, MD, Gentzler, Ryan D, MD, Martins, Renato G, Prof, Stevenson, James P, MD, Jalal, Shadia I, MBBS, Panwalkar, Amit, MD, Yang, James Chih-Hsin, Prof, Gubens, Matthew, MD, Sequist, Lecia V, MD, Awad, Mark M, MD, Fiore, Joseph, PharmD, Ge, Yang, PhD, Raftopoulos, Harry, MD, Gandhi, Leena, Prof

“…Summary Background Limited evidence exists to show that adding a third agent to platinum-doublet chemotherapy improves efficacy in the first-line advanced…”
Get full text

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway by Kurppa, Kari J., Liu, Yao, To, Ciric, Zhang, Tinghu, Fan, Mengyang, Vajdi, Amir, Knelson, Erik H., Xie, Yingtian, Lim, Klothilda, Cejas, Paloma, Portell, Andrew, Lizotte, Patrick H., Ficarro, Scott B., Li, Shuai, Chen, Ting, Haikala, Heidi M., Wang, Haiyun, Bahcall, Magda, Gao, Yang, Shalhout, Sophia, Boettcher, Steffen, Shin, Bo Hee, Thai, Tran, Wilkens, Margaret K., Tillgren, Michelle L., Mushajiang, Mierzhati, Xu, Man, Choi, Jihyun, Bertram, Arrien A., Ebert, Benjamin L., Beroukhim, Rameen, Bandopadhayay, Pratiti, Awad, Mark M., Gokhale, Prafulla C., Kirschmeier, Paul T., Marto, Jarrod A., Camargo, Fernando D., Haq, Rizwan, Paweletz, Cloud P., Wong, Kwok-Kin, Barbie, David A., Long, Henry W., Gray, Nathanael S., Jänne, Pasi A.

“…Eradicating tumor dormancy that develops following epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment of EGFR-mutant non-small…”
Get full text

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration by Drilon, Alexander, Clark, Jeffrey W., Weiss, Jared, Ou, Sai-Hong Ignatius, Camidge, D. Ross, Solomon, Benjamin J., Otterson, Gregory A., Villaruz, Liza C., Riely, Gregory J., Heist, Rebecca S., Awad, Mark M., Shapiro, Geoffrey I., Satouchi, Miyako, Hida, Toyoaki, Hayashi, Hidetoshi, Murphy, Danielle A., Wang, Sherry C., Li, Sherry, Usari, Tiziana, Wilner, Keith D., Paik, Paul K.

“…MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs) 1 . These alterations are associated with increased MET activity and…”
Get full text

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer by Ricciuti, Biagio, Recondo, Gonzalo, Spurr, Liam F, Li, Yvonne Y, Lamberti, Giuseppe, Venkatraman, Deepti, Umeton, Renato, Cherniack, Andrew D, Nishino, Mizuki, Sholl, Lynette M, Shapiro, Geoffrey I, Awad, Mark M, Cheng, Michael L

“…DNA damage response and repair (DDR) gene alterations are associated with increased tumor-infiltrating lymphocytes, higher genomic instability, and higher…”
Get full text

Imaging of Precision Therapy for Lung Cancer: Current State of the Art by Park, Hyesun, Sholl, Lynette M, Hatabu, Hiroto, Awad, Mark M, Nishino, Mizuki

“…Advances in characterization of molecular and genomic abnormalities specific to lung cancer have made precision therapy the current standard of care for lung…”
Get full text

Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer by Kehl, Kenneth L., Yang, Shihao, Awad, Mark M., Palmer, Nathan, Kohane, Isaac S., Schrag, Deborah

“…Introduction Patients with pre-existing autoimmune diseases have been excluded from clinical trials of immune checkpoint inhibitors (ICIs) for cancer…”
Get full text

Patient-derived models of acquired resistance can identify effective drug combinations for cancer by Crystal, Adam S., Shaw, Alice T., Sequist, Lecia V., Friboulet, Luc, Niederst, Matthew J., Lockerman, Elizabeth L., Frias, Rosa L., Gainor, Justin F., Amzallag, Arnaud, Greninger, Patricia, Lee, Dana, Kalsy, Anuj, Gomez-Caraballo, Maria, Elamine, Leila, Howe, Emily, Hur, Wooyoung, Lifshits, Eugene, Robinson, Hayley E., Katayama, Ryohei, Faber, Anthony C., Awad, Mark M., Ramaswamy, Sridhar, Mino-Kenudson, Mari, Iafrate, A. John, Benes, Cyril H., Engelman, Jeffrey A.

“…Targeted cancer therapies have produced substantial clinical responses, but most tumors develop resistance to these drugs. Here, we describe a pharmacogenomic…”
Get full text

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer by Wang, Xinan, Ricciuti, Biagio, Alessi, Joao V, Nguyen, Tom, Awad, Mark M, Lin, Xihong, Johnson, Bruce E, Christiani, David C

“…Despite the therapeutic efficacy of immune checkpoint inhibitors (ICIs) in a subset of patients, consistent and easily obtainable predictors of efficacy remain…”
Get full text

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer by Friboulet, Luc, Li, Nanxin, Katayama, Ryohei, Lee, Christian C, Gainor, Justin F, Crystal, Adam S, Michellys, Pierre-Yves, Awad, Mark M, Yanagitani, Noriko, Kim, Sungjoon, Pferdekamper, AnneMarie C, Li, Jie, Kasibhatla, Shailaja, Sun, Frank, Sun, Xiuying, Hua, Su, McNamara, Peter, Mahmood, Sidra, Lockerman, Elizabeth L, Fujita, Naoya, Nishio, Makoto, Harris, Jennifer L, Shaw, Alice T, Engelman, Jeffrey A

“…Non-small cell lung cancers (NSCLC) harboring anaplastic lymphoma kinase (ALK) gene rearrangements invariably develop resistance to the ALK tyrosine kinase…”
Get more information

Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials by Vora, Kruti B., Ricciuti, Biagio, Awad, Mark M.

“…Emerging retrospective and prospective studies indicate that immune checkpoint inhibitors (ICIs) can be safe and effective cancer treatments among people…”
Get full text

Germline variants associated with toxicity to immune checkpoint blockade by Groha, Stefan, Alaiwi, Sarah Abou, Xu, Wenxin, Naranbhai, Vivek, Nassar, Amin H., Bakouny, Ziad, El Zarif, Talal, Saliby, Renee Maria, Wan, Guihong, Rajeh, Ahmad, Adib, Elio, Nuzzo, Pier V., Schmidt, Andrew L., Labaki, Chris, Ricciuti, Biagio, Alessi, Joao Victor, Braun, David A., Shukla, Sachet A., Keenan, Tanya E., Van Allen, Eliezer, Awad, Mark M., Manos, Michael, Rahma, Osama, Zubiri, Leyre, Villani, Alexandra-Chloe, Fairfax, Benjamin, Hammer, Christian, Khan, Zia, Reynolds, Kerry, Semenov, Yevgeniy, Schrag, Deborah, Kehl, Kenneth L., Freedman, Matthew L., Choueiri, Toni K., Gusev, Alexander

“…Immune checkpoint inhibitors (ICIs) have yielded remarkable responses but often lead to immune-related adverse events (irAEs). Although germline causes for…”
Get full text

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity by Mahadevan, Navin R, Knelson, Erik H, Wolff, Jacquelyn O, Vajdi, Amir, Saigí, Maria, Campisi, Marco, Hong, Deli, Thai, Tran C, Piel, Brandon, Han, Saemi, Reinhold, Bruce B, Duke-Cohan, Jonathan S, Poitras, Michael J, Taus, Luke J, Lizotte, Patrick H, Portell, Andrew, Quadros, Victor, Santucci, Alison D, Murayama, Takahiko, Cañadas, Israel, Kitajima, Shunsuke, Akitsu, Aoi, Fridrikh, Maya, Watanabe, Hideo, Reardon, Brendan, Gokhale, Prafulla C, Paweletz, Cloud P, Awad, Mark M, Van Allen, Eliezer M, Lako, Ana, Wang, Xi-Tao, Chen, Benjamin, Hong, Fangxin, Sholl, Lynette M, Tolstorukov, Michael Y, Pfaff, Kathleen, Jänne, Pasi A, Gjini, Evisa, Edwards, Robin, Rodig, Scott, Reinherz, Ellis L, Oser, Matthew G, Barbie, David A

“…Small cell lung carcinoma (SCLC) is highly mutated, yet durable response to immune checkpoint blockade (ICB) is rare. SCLC also exhibits cellular plasticity,…”
Get more information

Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models by Engstrom, Lars D, Aranda, Ruth, Lee, Matthew, Tovar, Elizabeth A, Essenburg, Curt J, Madaj, Zachary, Chiang, Harrah, Briere, David, Hallin, Jill, Lopez-Casas, Pedro P, Baños, Natalia, Menendez, Camino, Hidalgo, Manuel, Tassell, Vanessa, Chao, Richard, Chudova, Darya I, Lanman, Richard B, Olson, Peter, Bazhenova, Lyudmilla, Patel, Sandip Pravin, Graveel, Carrie, Nishino, Mizuki, Shapiro, Geoffrey I, Peled, Nir, Awad, Mark M, Jänne, Pasi A, Christensen, James G

“…exon 14 deletion ( ex14 del) mutations represent a novel class of non-small cell lung cancer (NSCLC) driver mutations. We evaluated glesatinib, a…”
Get full text

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade by Akbay, Esra A, Koyama, Shohei, Liu, Yan, Dries, Ruben, Bufe, Lauren E, Silkes, Michael, Alam, Md Maksudul, Magee, Dillon M, Jones, Robert, Jinushi, Masahisa, Kulkarni, Meghana, Carretero, Julian, Wang, Xiaoen, Warner-Hatten, Tiquella, Cavanaugh, Jillian D, Osa, Akio, Kumanogoh, Atsushi, Freeman, Gordon J, Awad, Mark M, Christiani, David C, Bueno, Raphael, Hammerman, Peter S, Dranoff, Glenn, Wong, Kwok-Kin

“…Proinflammatory cytokine interleukin-17A (IL-17A) is overexpressed in a subset of patients with lung cancer. We hypothesized that IL-17A promotes a…”
Get more information